Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CL and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CL and 80,000+ other tickers.
See exactly how CL's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CL and 80,000+ other tickers.
Operating globally, Colgate-Palmolive Company and its affiliated entities are engaged in the production and distribution of a diverse range of consumer goods. Its operations are structured into two primary divisions: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care division encompasses a broad array of offerings, spanning oral hygiene (e.g., toothpastes, toothbrushes, mouthwashes), personal care (e.g., bar and liquid soaps, shower gels, shampoos, conditioners, deodorants, antiperspirants, skin health items), and home care solutions (e.g., dishwashing…
Dividend investors can find amazing yields among the largest consumer brands.
Some dividend stocks raise their payouts through one recession, maybe two.
Baypointe Partners LLC reduced its stake in Colgate-Palmolive Company (NYSE: CL) by 80.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,000 shares of the company's stock after selling 40,000 shares during the quarter. Colgate-Palmolive makes up approximately
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Colgate-Palmolive remains a Buy, offering defensive qualities, a resilient global portfolio, and an attractive margin of safety at current valuation. Q2 results showed 4.9% net sales growth and 8% base EPS growth, with strong performance outside North America and continued innovation driving market share gains. CL maintains robust free cash flow, supports a 2.36% dividend yield, and continues share repurchases, underpinned by manageable debt and disciplined capital allocation.